Skip to main content

Department of Chemistry Archives

Personalized Structural Biology aids cancer treatment decisions

Apr. 8, 2021—Cancer specialists at Vanderbilt University Medical Center, in partnership with biochemists and structural biologists across the Vanderbilt University campus, are taking “personalized” cancer therapy to a new level.

Read more


Cancer’s SOS

Mar. 28, 2019—Stephen Fesik and colleagues are advancing cancer drug discovery with the characterization of small molecules that modulate RAS, an important target for anti-cancer therapies.

Read more


Designing antibodies to fight the flu

Jan. 31, 2019—Vanderbilt investigators said their work shows that computational design can improve the ability of naturally occurring antibodies to recognize different flu strains and may hasten the development of more effective flu therapies and vaccines.

Read more


DNA’s on/off switch

Jan. 17, 2019—DNA-binding “switches” represent a fundamentally new method of communication between DNA-processing enzymes, Vanderbilt researchers propose.

Read more


New view of the heartbeat

Apr. 6, 2018—Structural views of the proteins that regulate the heartbeat may help improve existing treatments for cardiac arrhythmias.

Read more


Transcription factor evolution

Aug. 11, 2016—Vanderbilt researchers have discovered a novel model of evolution for factors that control gene expression.

Read more


VU investigators use magnetism to help isolate malaria biomarker

Jan. 21, 2016—Vanderbilt investigators have developed a way to detect malaria that is faster and more sensitive than current clinical methods — a development that has the potential to make malaria detection significantly less expensive and more stable.

Read more


Chazin honored with international biophysics award

Oct. 22, 2015—Walter Chazin, Ph.D., director of the Vanderbilt Center for Structural Biology, is a recipient of a 2016 Fellow of the Biophysical Society award.

Read more


The yin and yang of COX-2

Oct. 2, 2015—New findings add to the understanding of how the enzyme COX-2 works, which is critical to the development of COX-2-targeted anti-inflammatory drugs.

Read more


Collaboration seeks to develop new therapies for bone, other diseases

Oct. 1, 2015—La Jolla Pharmaceutical Co. and Vanderbilt University have signed a research and license agreement covering Vanderbilt’s research program and intellectual property rights related to compounds that block bone morphogenetic protein (BMP) type-I receptors. The compounds have therapeutic potential in a broad range of diseases, including rare genetic disorders.

Read more


Framework for studying cell responses

Aug. 26, 2015—Vanderbilt investigators have developed a framework for studying cellular responses that could be used to identify the agents driving a range of biological processes in health and disease.

Read more


Bridging the antibiotic gap

Aug. 7, 2015—Vanderbilt researchers have discovered how certain molecules with antibiotic properties are synthesized, findings that could lead to new drugs that overcome the increased antibiotic resistance in bacteria.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more